University of Chicago Licenses PGx Test to Mayo

University of Chicago researchers licensed a pharmacogenomics test for colorectal cancer patients to the Mayo Clinic, the university said two weeks ago.

The UGT1A1 test determines which patients are likely to have an adverse reaction to Pfizer's Camptosar, a key component of the standard first-line treatment for advanced cancers of the colon and rectum.

Through this licensing agreement, the clinic's reference laboratory, Mayo Medical Laboratories, will provide the test to patients nationwide.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.